AKM Lab-01

PreclinicalSmall molecule

MMoon (Guangzhou) Biotechnology Co., Ltd.

AKM Lab-01 is one of 4 small molecule programs targeting Overweight , Obesity. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Overweight , ObesityRecruiting

Overweight , ObesityPreclinical

Recruiting

Competition

Competitive Landscape

6 competitors in Overweight , Obesity

#DrugCompanyPhaseTrials

Mwn109 1

SShanghai Minwei Biotechnology Co., Ltd

Phase 3

6 2

Mwn109 2

SShanghai Minwei Biotechnology Co., Ltd

Phase 3

6 3

Mwn109 3

SShanghai Minwei Biotechnology Co., Ltd

Phase 3

5 4

AKM Lab-01

MMoon (Guangzhou) Biotechnology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Overweight , Obesity

NCT07331974

Clinical

Trials by Indication[1]

Overweight , Obesity1 trial

A Randomized, Double-blind, Placebo-controlled Trial to Access the Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 in Participents With Overweigh and Obesity

Recruiting·MMoon (Guangzhou) Biotechnology Co., Ltd.·Preclinical·NCT07331974·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AKM Lab-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AKM Lab-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AKM Lab-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moon (Guangzhou) Biotechnology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMoon (Guangzhou) Biotechnology Co., Ltd.

AKM Lab-01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Overweight , Obesity1 trial

References

Drug Info

Quick Facts

Related News